UNIVERSITY OF SOUTHERN CALIFORNIA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1880-01-01

Employees: 10K

Market Cap: -

Website: http://startusc.com

Clinical Trials

Genetics of Beta Cell Failure in Mexican Americans

Completed

Conditions: Gestational Diabetes
Physical Activity
Adipokines
Air Pollution
Genetics
Nutrition
Insulin Resistance
Obesity
Diabetes Type 2
Beta Cell Function

First Posted Date: 2017-10-04

Last Posted Date: 2023-11-18

Lead Sponsor: University of Southern California

Target Recruit Count: 1250

Registration Number: NCT03301519

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Not Applicable

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Perflutren Lipid Microspheres
Drug: Sulfur Hexafluoride Lipid Microspheres
Device: Dynamic Contrast-Enhanced Ultrasound Imaging
Device: Positron Emission Tomography
Device: Computed Tomography
Biological: Yttrium-90 (90Y)

First Posted Date: 2017-10-03

Last Posted Date: 2019-05-16

Lead Sponsor: University of Southern California

Registration Number: NCT03300401

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Phase 3

Terminated

Conditions: Colorectal Adenocarcinoma
Stage IIIB Colorectal Cancer AJCC v7
Stage IIIC Colorectal Cancer AJCC v7
Stage III Colorectal Cancer AJCC v7
RAS Wild Type
Stage IIIA Colorectal Cancer AJCC v7
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions: Biological: Panitumumab
Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Other: Quality-of-Life Assessment
Drug: Capecitabine
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-03

Last Posted Date: 2020-06-11

Lead Sponsor: University of Southern California

Target Recruit Count: 4

Registration Number: NCT03300609

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Addressing Uncontrolled Diabetes in Primary Care: A Lifestyle Redesign Approach

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Behavioral: Lifestyle Redesign

First Posted Date: 2017-09-26

Last Posted Date: 2020-03-24

Lead Sponsor: University of Southern California

Target Recruit Count: 143

Registration Number: NCT03293914

Locations: 🇺🇸
LAC+USC Primary Care Adult West Clinic, Los Angeles, California, United States

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Not Applicable

Terminated

Conditions: Cancer Survivor
No Evidence of Disease
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Obesity
Overweight
Stage IIIC Breast Cancer
Sedentary Lifestyle
Stage I Breast Cancer
Stage IB Breast Cancer

Interventions: Behavioral: Exercise Intervention
Other: Laboratory Biomarker Analysis
Device: Monitoring Device
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-09-15

Last Posted Date: 2020-05-12

Lead Sponsor: University of Southern California

Target Recruit Count: 23

Registration Number: NCT03284346

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty

Conditions: Pulmonary Embolism

First Posted Date: 2017-09-07

Last Posted Date: 2023-11-18

Lead Sponsor: University of Southern California

Target Recruit Count: 100

Registration Number: NCT03275610

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Phase 2

Active, not recruiting

Conditions: Vulvar High Grade Squamous Intraepithelial Lesion
Cervical Squamous Cell Carcinoma In Situ

Interventions: Drug: Cyclophosphamide
Drug: Indomethacin
Biological: IRX-2
Other: Laboratory Biomarker Analysis
Dietary Supplement: Multivitamin
Other: Placebo
Drug: Omeprazole
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-08-30

Last Posted Date: 2024-10-10

Lead Sponsor: University of Southern California

Target Recruit Count: 11

Registration Number: NCT03267680

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Topical Treatment and Prevalence of P. Acnes

Phase 2

Completed

Conditions: Surgical Site Infection

Interventions: Drug: Clindamycin 1% Gel
Drug: Benzoyl peroxide 5% gel
Drug: BenzaClin 5%-1% Topical Gel

First Posted Date: 2017-08-22

Last Posted Date: 2019-11-13

Lead Sponsor: University of Southern California

Target Recruit Count: 12

Registration Number: NCT03257202

Locations: 🇺🇸
Keck School of Medicine of the University of Southern California, Los Angeles, California, United States

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Gallbladder Carcinoma
Stage III Gallbladder Cancer AJCC V7
Stage IIIB Gallbladder Cancer AJCC v7
Gallbladder Adenocarcinoma, Biliary Type
Stage IIIA Hepatocellular Carcinoma AJCC v7
Stage IIIB Hepatocellular Carcinoma AJCC v7
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type
Recurrent Hepatocellular Carcinoma
Recurrent Pancreatic Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v7

Interventions: Biological: Durvalumab
Drug: Guadecitabine

First Posted Date: 2017-08-22

Last Posted Date: 2024-07-10

Lead Sponsor: University of Southern California

Target Recruit Count: 55

Registration Number: NCT03257761

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Intra-articular Adipose Tissue Injections for Osteoarthritis

Not Applicable

Conditions: Osteoarthritis, Knee

Interventions: Biological: Autologous adipose tissue injection
Drug: Hyaluronic Acid

First Posted Date: 2017-08-08

Last Posted Date: 2019-10-03

Lead Sponsor: University of Southern California

Target Recruit Count: 54

Registration Number: NCT03242707

Locations: 🇺🇸
Keck Medicine of USC, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy